Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis
Zoé Van de Wyngaert, Irene Romera-Martinez, Céline Chedeville, Paolo Musiu, Souhila Ikhlef, Bénédicte Jonca, Mohamad Mohty, Florent Malard
Abstract
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.
Topics & Concepts
Multiple myelomaMedicineImmunoglobulin light chainAntibodyDialysisPlasma cellAntigenInternal medicineUrologyOncologyImmunologyMultiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchHIV/AIDS drug development and treatment